The Percentage of Cases of Acute Treatment With Allopurinol in Gout Patients
Sponsor
Hillel Yaffe Medical Center (Other)
Overall Status
Unknown status
CT.gov ID
NCT03601260
Collaborator
(none)
700
1
1
4
174.6
Study Details
Study Description
Brief Summary
The aim of the study is to determine the percentage of cases of acute treatment with Allopurinol in gout patients who have been previously treated.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| N/A |
Study Design
Study Type:
Interventional
Anticipated Enrollment
:
700 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
To Examine the Percentage of Cases of Acute Treatment With Allopurinol in Gout Patients as Secondary Treatment
Anticipated Study Start Date
:
Aug 1, 2018
Anticipated Primary Completion Date
:
Dec 1, 2018
Anticipated Study Completion Date
:
Dec 1, 2018
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: Gout Patients Allopurinol 100 mg-300mg/day as secondary treatment in gout patients |
Drug: Allopurinol
Treatment of gout patients by oral dosage of 100 mg-300mg/ day of Allopurinol
|
Outcome Measures
Primary Outcome Measures
- Gout patients treated with Allopurinol [Six months]
Retrospective identification through medical records of percentage of gout patients treated with Allopurinol
Secondary Outcome Measures
- Patients with contraindication to Allopurinol [Six months]
Retrospective identification through medical records of percentage of gout patients with contraindications to Allopurinol
Eligibility Criteria
Criteria
Ages Eligible for Study:
25 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- Gout patients
Exclusion Criteria:
-
Pregnant women
-
Chronic renal failure
-
Patients with Allopurinal hypersensitivity
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hillel Yaffe Medical Center | Hadera | Israel | 38100 |
Sponsors and Collaborators
- Hillel Yaffe Medical Center
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier:
NCT03601260
Other Study ID Numbers:
- HYMC-FKH-1
First Posted:
Jul 26, 2018
Last Update Posted:
Jul 26, 2018
Last Verified:
Jul 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: